Wedbush Has Pessimistic Outlook of TCRX FY2026 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at Wedbush dropped their FY2026 earnings per share estimates for TScan Therapeutics in a research report issued to clients and investors on Tuesday, December 10th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.97) per share for the year, down from their prior forecast of ($0.96). Wedbush has a “Outperform” rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ FY2027 earnings at ($1.02) EPS and FY2028 earnings at ($0.94) EPS.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.03. The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.

A number of other brokerages have also issued reports on TCRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research note on Wednesday. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research note on Wednesday.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX opened at $3.02 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The business has a 50-day simple moving average of $4.87 and a two-hundred day simple moving average of $5.91. TScan Therapeutics has a fifty-two week low of $2.60 and a fifty-two week high of $9.69.

Insider Activity at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke purchased 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was purchased at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the purchase, the director now directly owns 45,000 shares in the company, valued at approximately $238,050. This trade represents a 12.50 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.76% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP purchased a new position in TScan Therapeutics in the 2nd quarter worth approximately $70,000. SG Americas Securities LLC acquired a new stake in TScan Therapeutics during the third quarter worth $78,000. The Manufacturers Life Insurance Company purchased a new stake in TScan Therapeutics in the second quarter valued at $90,000. XTX Topco Ltd acquired a new position in shares of TScan Therapeutics in the 3rd quarter valued at $112,000. Finally, MetLife Investment Management LLC increased its position in shares of TScan Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after purchasing an additional 13,164 shares during the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.